Abivax (ABVX) Profit After Tax (2022 - 2026)

Abivax's Profit After Tax history runs 5 years deep, the most recent figure standing at $56.7 million for Q1 2026.

• On a quarterly basis, Profit After Tax rose 3.01% year-over-year to $56.7 million in Q1 2026; TTM through Mar 2026 was -$396.2 million, a 123.8% decrease from a year earlier, with the FY2025 full-year figure at -$391.2 million, down 105.15% from the prior year.
• Profit After Tax climbed to $56.7 million in Q1 2026 per ABVX's latest filing, from -$687.1 million in the prior quarter.
• Across five years, Profit After Tax topped out at $179.3 million in Q3 2025 and bottomed at -$687.1 million in Q4 2025.
• The 5-year median for Profit After Tax is $46.6 million (2024), against an average of -$47.9 million.
• Across the five-year window, Profit After Tax sank 210940865.76% in 2024 and surged 195.6% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$61.93 in 2022, then sank by 156.09% to -$158.59 in 2023, then sank by 210940865.76% to -$334.5 million in 2024, then sank by 105.38% to -$687.1 million in 2025, then soared by 108.26% to $56.7 million in 2026.
• Per Business Quant, the three latest ABVX Profit After Tax figures stand at $56.7 million (Q1 2026), -$687.1 million (Q4 2025), and $179.3 million (Q3 2025).